人ProIGF-II E(78 - 88)抗血清通過用衍生自連接到白喉類毒素的人IGF-II E的E結(jié)構(gòu)域的11個(gè)氨基酸的肽免疫兔來制備。 該序列對(duì)應(yīng)于IGF-II E77 - 88,因此,抗血清識(shí)別全長(zhǎng)IGF-II E和兩種IGF-II E變體(IGF-II E1 - 88和IGF-II E1 - 104),這兩種變體來源于人igf-2基因的加工和隨后的蛋白水解切割。 它不識(shí)別成熟的IGF-II或IGF-I。 序列分析表明,它可能識(shí)別非人靈長(zhǎng)類動(dòng)物、狗、豚鼠、豬和許多其他物種中的IGF-II E蛋白。 Human ProIGF-II E (78-88) antiserum was prepared by immunising rabbits with an 11 amino acid peptide derived from the E domain of human IGF-II E linked to diphtheria toxoid. The sequence corresponds to IGF-II E77-88and as a consequence, the antiserum recognises full length IGF-II E and both IGF-II E variants (IGF-II E1-88 andIGF-II E1-104)derived from processing of the human igf-2 gene and following proteolytic cleavage. It does not recognise mature IGF-II or IGF-I. Sequence analysis suggests it is likely to recognise IGF-II E proteins in non-human primates, dog, guinea-pig, pig and a number of other species.
GroPep Bioreagents公司總部位于澳大利亞,成立于1990年,致力于向廣大科研院所、生物技術(shù)及制藥公司開發(fā)、生產(chǎn)和銷售細(xì)胞培養(yǎng)級(jí)的活性生長(zhǎng)因子(主要集中在胰島素樣生長(zhǎng)因子(IGF)領(lǐng)域)、抗體及相關(guān)蛋白試劑,現(xiàn)有產(chǎn)品超過100多個(gè),同時(shí)在世界范圍內(nèi)均設(shè)有分銷商。公司在分子生物領(lǐng)域、發(fā)酵學(xué)及重組蛋白和單抗制備方面具有豐富的經(jīng)驗(yàn),在制造工藝方面,擁有大量專利技術(shù),GroPep目前已通過AS/NZS ISO 9001:2016質(zhì)量管理體系認(rèn)證。